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0929-6646/Copyright ª 2015, Formosa
BY-NC-ND license (http://creativecomBackground/purpose: Multidrug-resistant tuberculosis (MDR-TB) represents 5% of TB cases
globally. In Egypt, it represents 11.4% of TB cases (2.2% of new and 38.2% of previously
treated). Our objectives were to evaluate the treatment outcomes and determine the associ-
ated prognostic factors among the first national treatment cohort of MDR-TB from 2006 to
2010.
Methods: All patients diagnosed with MDR-TB from July 2006 to December 2010 who were
admitted to Abbassia Chest Hospital, the first Egyptian national center established for MDR-
TB treatment, were included. They were followed up clinically, radiologically, and bacterio-
logically by sputum smear, culture, and drug-susceptibility testing at regular intervals. Individ-
ualized treatment regimens were prescribed according to each patient’s drug-susceptibility
testing and the drug treatment history. Patients received at least five effective drugs.
Outcome rates, and crude and adjusted odds ratios of unsuccessful outcomes were calculated.
Results: The number of bacteriologically proven MDR-TB patients was 228, of which 225 were
pulmonary cases. Half of the cases showed moderate or extensive lung lesions, and 15.8% were
diabetics. A total of 158 (119 cured and 39 completed treatment) patients achieved successful
outcome (69.3%), 16 (7.1%) failed treatment, 27 (11.8%) were lost to follow up, and 27 (11.8%)
died. Predictors of unsuccessful outcome were delay in sputum culture conversion to 2 months
or more, moderate or extensive lung lesions, and a history of diabetes.
Conclusion: A treatment success rate of approximately 69% was achieved with the first na-
tional treatment cohort of MDR-TB under the Egyptian program. Predictors of unsuccessfulave no conflicts of interest relevant to this article.
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998 M.A. Gadallah et al.treatment were delayed culture conversion, moderate or extensive lung affection, and
diabetes.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction DefinitionsMultidrug-resistant tuberculosis (MDR-TB) is defined as
resistance to at least the two key first-line drugs: isoniazid
and rifampicin. Resistance mainly arises through the se-
lection of mutated strains by improper or inadequate
treatment.1 Globally, MDR-TB is estimated to account for
5% of TB cases, being higher among patients previously
treated for TB (20.5%), than among new cases (3.5%).2 The
more resistant form of TB, extensively drug-resistant TB,
was reported from 92 countries in the year 2012, and it is
estimated to account for 9.6% of MDR-TB cases.3 Treatment
of MDR-TB is a lengthy regimen using mainly bacteriostatic,
less effective, and more toxic drugs, and thus is poorly
tolerated. Consequently, adherence is extremely difficult,
and a disappointingly low average global success rate of
48%, with high rates of both mortality and loss to follow up,
was reported. Proper operational and clinical case man-
agement is essential for treatment success.1,3
The Egyptian National Tuberculosis Control Program
adopted the World Health Organization’s strategy of
Directly Observed Treatment with Short Course (DOTS) in
1996, and a nationwide coverage was reached by the year
2000. In 2002, a drug resistance survey was conducted with
the detection of MDR-TB in 11.4% of the total TB cases (97
out of 849), of which 2.2% were among new cases (14 out of
632) and 38.2% among previously treated cases (83 out of
217).4 The magnitude of MDR-TB cases was noticeable,
especially among previously treated cases. Therefore, in
2003, Egypt applied to the Green Light Committee to
establish a project for their management, planning to
include four centers covering the whole country. The first
center was in Abbassia Chest Hospital in July 2006, and
three other centers are now established. The objectives of
the current study were to evaluate the treatment outcomes
and determine the associated prognostic factors among the
first national treatment cohort of MDR-TB patients in
Abbassia Chest Hospital from 2006 to 2010.Methods
Setting and study design
Abbassia Chest Hospital was chosen as the first center for
starting the national program of treatment of MDR-TB pa-
tients in Egypt. It is one of the biggest Egyptian chest
hospitals, located in Cairo, with a capacity of 450 beds. A
prospective cohort study was carried out including all the
patients admitted during the study period (from June 2006
to December 2010). Patients were retrieved from all over
the country to constitute the first national treatment
cohort of MDR-TB.Case definitions, definition of sputum conversion, and
treatment outcome definitions were according to the rec-
ommendations of the World Health Organisation MDR-TB
working group.5 Cured patients were those who had
completed treatment according to the protocol and had at
least five consecutive negative cultures, 30 days apart in
the final 12 months of treatment. Cure could still be
considered in cases reporting only one positive culture
during that time, followed by a minimum of three consec-
utive negative ones with no clinical deterioration. Treat-
ment completed cases included patients who had
completed treatment according to the protocol, but fewer
than five cultures were performed during the final 12
months of treatment.5 Successful outcome included both
cured and completed patients.Laboratory testing
Sputum smear microscopy and culture on Low-
ensteineJensen media were conducted in the laboratory of
Abbassia Chest Hospital and according to the international
standards. Drug-susceptibility testing (DST) was conducted
in the national reference laboratory, which was chosen to
be the supranational laboratory for the Eastern Mediterra-
nean Region of the World Health Organization (WHO). DST
was conducted for four first-line drugs (isoniazid, rifam-
picin, ethambutol, and streptomycin) and for three second-
line drugs (capreomycin, amikacin, and ofloxacin). Testing
was performed monthly until conversion and then every
other month. DST was reassessed in cases with delayed
conversion beyond the 3rd month of treatment, or in cases
where cultures became positive after being negative
previously.
Other scheduled investigations including assessment of
serum glucose, creatinine, potassium, thyroid stimulating
hormone (TSH), liver enzymes, and pregnancy test were
performed. Human immunodeficiency virus status was
assessed and all patients were negative.Radiographic testing
Disease extension on the standard chest X-ray film (poste-
rioreanterior) was categorized as follows: milddincluded
unilateral disease infiltration and unilateral cavity; mod-
eratedincluded bilateral cavity or complete lobe destruc-
tion; and extensivedincluded any wider extension of the
disease. Radiography was performed at patient enrollment
and every 6 months thereafter.
Table 1 Demographics, clinical characteristics, and
treatment outcome.
Characteristics n Z 228 (%)
Age < median valuea 106 (46.5)
Age  median value 122 (53.5)
Male sex 161 (70.6)
Smoking 83 (36.4)
Alcohol use 21 (09.2)
Illicit drug use 26 (11.4)
Pulmonary TB 225 (98.7)
Disease duration before treatment:  5 yb 35 (15.8)
History of diabetes 36 (15.8)
Previous use of any of second-line drugsc 26 (11.4)
Resistance to four or more drugs 180 (78.9)
Moderate and extensive lesions in X-rayd 113 (50.2)
Drug regimens
IdKm, Ofx, Cs, Eto, PAS 209 (91.7)
IIdCm, Lfx, Cs, Eto, PAS, Clr, Amx/Clv 10 (4.4)
IIIdE, Km, Ofx, Cs, Eto, PAS 9 (3.9)
Sputum smear conversion before 2 mod 114 (50.7)
Sputum culture conversion before 2 mod 48 (21.3)
Successfule 158 (69.3)
Failure 16 (7.10)
Lost to follow up 27 (11.8)
Deaths 27 (11.8)
Amx/Clv Z amoxicillin/clavulanate; Clr Z clarithromycin;
Cm Z capreomycin; Cs Z cycloserine; E Z ethambutol;
Eto Z ethionamide; Km Z kanamycin; Lfx Z levofloxacin;
Ofx Z ofloxacin; PAS Z p-aminosalicylic acid;
TB Z tuberculosis.
a Median age Z 37 years.
b Percentage was taken from the 222 previously treated cases.
c Drugs either administered with Category IV regimen (7
cases) or sporadically used (19 cases).
d Percentage was taken from the 225 pulmonary TB cases.
e A total of 119 patients was cured and 39 completed the
treatment period.
Prognostic factors of treatment of MDR-TB in Egypt 999Treatment regimens
The MDR-TB patients who were confirmed by drug-suscep-
tibility tests (DST) were put on an individualized treatment
regimen based on the resistance profile of the patients to
the first-line anti-TB treatment and modified according to
their treatment history. Treatment duration was 18 months
after sputum culture conversion, as recommended by the
WHO.6
All doses of drugs were directly observed during hospi-
talization and three times a week during the ambulatory
period.
Statistical analysis
Data analysis was performed using SPSS version 20 (IBM
Corp. Released 2011. IBM SPSS Statistics for Windows,
Version 20.0. Armonk, NY: IBM Corp. US). Categorical vari-
ables were compared using either Chi-square or Fisher’s
exact test. Crude and adjusted odds ratios (ORs) and their
95% confidence intervals (CI95) were calculated. A binary
logistic multivariate model was applied to determine the
independent predictors of the treatment outcome out of
those factors that demonstrated significant association by
bivariate analysis at a level of significance of p  0.05.
Ethical approval
Research Ethics C at the Faculty of Medicine, Ain Shams
University, approved this study protocol. A formal,
informed written consent was obtained from every patient
prior to starting the treatment.
Results
From 2006 until the end of 2010, 228 MDR-TB patients were
admitted to Abbassia Chest Hospital. Their characteristics
are reported in Table 1. The median age was 37 years,
ranging from 7 years to 76 years. The number of female
patients was 67 (29.4%). On hospital admission, 36.4% were
smokers, 9.2% were alcohol users, and 11.4% were illicit
drug users.
Extrapulmonary TB was diagnosed in three patients
(1.3%). The number of new cases was six (2.6%); the ma-
jority of the patients were previously treated cases (222/
228, 97.4%), among them 124 (55.9%) had previously
received more than two treatment courses. The number of
treatment courses ranged from one to seven, and the me-
dian was three. A history of TB illness for <5 years before
starting treatment was most common (187/222, 84.2%).
Twenty-six (26/228, 11.4%) patients had a positive history
of receiving the second-line anti-TB drugs.
Isolates were resistant to a median of four drugs (range
2e6), and the vast majority were resistant to streptomycin
(220/228, 96.5%) and ethambutol (183/228, 80.3%). Resis-
tance to fluoroquinolones, except ofloxacin (3/228, 1.3%),
was uncommon. Resistance to the second-line injectable
drug kanamycin was detected in cases with extensively
drug-resistant TB (2/228, 0.9%). Of the isolates, 180 (78.9%)
were resistant to at least four drugs. Lung lesions were mildin 49.8% (112/225), moderate in 23.1% (52/225), and
extensive in 27.1% (61/225) of the pulmonary cases. Dia-
betes was found among 15.8% (36/228) of patients.
At least five effective drugs (range 5e7) were used for a
median duration of 22 months (range 21e30 mo) for 174
(76.3%) patients (excluding deaths and those lost to follow
up). Taking into consideration the patients’ resistance
profile and treatment history, three treatment regimens
were used: Regimen Idkanamycin, ofloxacin, cycloserine,
ethionamide, and p-aminosalicylic acid (209/228, 91.7%);
Regimen IIdcapreomycin, levofloxacin, cycloserine, ethi-
onamide, p-aminosalicylic acid, amoxicillin/clavulanate,
and clarithromycin (10/228, 4.4%); and Regimen III-
dethambutol, kanamycin, ofloxacin, cycloserine, ethion-
amide, and p-aminosalicylic acid (9/228, 3.9%).
The median time of sputum smear conversion to nega-
tive was 30 days (ranging from 27 d to 183 d). Conversion
occurred in 114 (50.7%) patients before 2 months of treat-
ment had elapsed, and they most probably became nonin-
fectious. No conversion occurred in 16 (7.1%) patients.
The median time of sputum culture conversion was 60
days (interquartile range 58e121 d). Conversion before 2
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tween 2e3 months in 93 (41.3%) patients, and after 3
months in 56 (24.9%) patients, with a maximum of 10
months. No conversion occurred in 28 (12.4%) patients.
As shown in Table 1, about half of the patients were
cured (n Z 119, 52.2%) and 39 (17.1%) completed the
treatment, giving a successful outcome (cured and
completed) in 158 (69.3%) patients. Treatment failure was
declared in 16 (7.1%) patients, 27 (11.8%) were lost to
follow up, and 27 (11.8%) died. The three extrapulmonary
cases either completed treatment (2 patients) or were lost
to follow up (1 patient).
Using the bivariate analysis (Table 2), the rate of un-
successful outcome was found to be significantly higher
among males (OR: 2.6, CI95: 1.3e5.2, p Z 0.007), smokers
(OR: 2.3, CI95: 1.3e4.1, p Z 0.005), alcohol users (OR:
2.8, CI95: 1.1e6.8, p Z 0.024), drug users (OR: 2.5, CI95:
1.1e5.8, p Z 0.023), diabetics (OR: 2.3, CI95: 1.1e4.9,
p Z 0.02), those with a positive history of intake of the
second-line anti-TB drugs (OR: 3.6, CI95: 1.6e8.4,
pZ 0.002), those with moderate or extensive lung lesions
on X-ray (OR: 4.3, CI95: 2.3e8.1, p Z 0.000), and those
whose culture conversion was delayed to 2 months or
more (OR: 3.6, CI95: 1.2e10.8, p Z 0.001). Treatment
outcome was not affected by age, patient’s category
(either previously treated or new case), number of drugs
to which isolates were resistant, or the treatment
regimen.
The median treatment durations were 22 months (range
21e30 mo) among successful and 23 months (range
21e26 mo) among unsuccessful treatment outcome groups.
The difference in treatment duration was not statistically
significant (t test Z 0.964, p Z 0.336). On multivariate
analysis, significant predictors of an unsuccessful outcome
were diabetes (OR: 2.7, CI95: 1.02e6.99), moderate or
extensive lung lesion (OR: 5.9, CI95: 2.5e13.9), and delay in
sputum culture conversion to 2 months or more (OR: 3.7,
CI95: 1.2e11.7).Discussion
In this first national treatment cohort of MDR-TB patients,
the achieved success rate was 69.3%. Rates of failure, loss
to follow up, and death were 7.1%, 11.8%, and 11.8%,
respectively. Application of individualized treatment regi-
mens for at least 18 months after sputum culture conver-
sion was performed, as well as application of DOTS strictly
during the period of hospitalization and for two to three
times weekly afterward.
Studies evaluating the performance of different country
programs showed that the rates of treatment success
ranged from 62% to 69%, failure from 6% to 8%, loss to follow
up from 12% to 15%, and death from 9% to 13%.7e9 Programs
applying individualized treatment regimens for a duration
of more than 18 months and DOTS strategy throughout this
period achieved the highest success rate and reduced loss
to follow up rate.7e10 Their average rates of treatment
success, failure, loss to follow-up, and death were 69%, 7%,
12%, and 9%, respectively.7 Apart from the higher rate of
death, our results showed comparability to other programs
applying the same conditions.The observed higher mortality might be due to the fact
that most of the mortality cases (19 out of 27, 70.4%)
showed moderate or severe lung lesion. These findings
might be a result of the fact that a long time elapsed be-
tween their diagnoses as MDR-TB cases and the start of
treatment; as the establishment of the MDR-TB manage-
ment program began late in June 2006 in only one center
(the study site); this delay might have negatively affected
their outcome. Lower mortality and a lower rate of treat-
ment failure can be observed in programs with a shorter
delay in treatment commencement for MDR-TB patients, as
well as in treatment cohorts with a higher percentage of
those who had had no previous anti-TB therapy.8,11,12
Treatment delay might not be a problem with the patient
group that started treatment later, and the application of
rapid diagnostic techniques might be an opportunity for
improvement of the program performance.
Many predictors of treatment outcome among MDR-TB
cases have been identified through various studies. The
results herein documented the association of unsuccessful
outcome, using bivariate analysis, with the male sex,
smoking, alcohol use, illicit drug use, a history of diabetes,
a history of previous use of a second-line anti-TB drugs,
moderate or extensive lung lesions, and delay in sputum
culture conversion to negative to 2 months or more. How-
ever, only three independent factors were identified by
multivariate analysis, namely, a history of diabetes, mod-
erate or extensive lung lesions, and delay in culture con-
version to 2 months or more of treatment.
Poor treatment outcome was reported, in a number of
previous studies, to be associated with factors such as male
sex, alcohol usage, illicit drugs usage, and smoking.8,13e16
However, the role of sex was not documented in two
studies conducted in India and Switzerland.17,18 Our data
could not provide sufficient evidence to document the role
of any of these factors in prediction of treatment outcome.
Previous and inadequate TB treatment, and a previous
use of second-line drugs have been documented as signifi-
cant risk factors for poor treatment outcome due to the
development of more drug resistance.8,19,20 Despite the
number of studies that documented this fact, the data
herein did not prove any of these factors. The insufficient
sample of new MDR cases (6 patients) limited our ability to
evaluate the effect of previous TB treatment, since previ-
ous treatment was reported in 97.4% of our sample.
Neither the treatment regimen nor the initial resistance
to a greater number of drugs was found to have an effect
on the outcome. Some studies also reported that the
outcome was not affected by the regimen used or the
patients’ resistance profile.9,18 The small sample that
received either the second (10 patients) or the third (9
patients) regimen, as well as the slight differences be-
tween them may explain the inability to demonstrate any
effect of each regimen on the outcome. The risk of poor
treatment outcome among diabetics was about three times
that among nondiabetics. The role of diabetes in both the
development of resistance and the risk of treatment fail-
ure and death among MDR-TB patients has been exten-
sively studied. The relationship between diabetes mellitus
and MDR-TB is a point of controversy. While some studies
could not find such a relation,21e23 others observed an
increased risk of MDR-TB, ranging from 2.1 to 8.8 times,
Table 2 Factors affecting treatment success among MDR-TB patients (n Z 228).
Unsuccessful
n Z 70 (30.7%)
Successful
n Z 158 (69.3%)
p Crude OR (CI95) Adjusted OR (CI95)
a
Sex
Male 58 (36.0) 103 (64.0) 0.007 2.6 (1.3e5.2) 2.3 (0.9e5.9)
Female 12 (17.9) 55 (82.1)
Age category (y)
37 44 (36.1) 78 (63.9) 0.061 1.7 (0.9e3.1) ND
<37 26 (24.5) 80 (75.5)
Tobacco use
Smokers 35 (42.2) 48 (57.8) 0.005 2.3 (1.3e4.1) 1.4 (0.5e3.5)
Nonsmokers 35 (24.1) 110 (75.9)
Alcohol use
Users 11 (52.4) 10 (47.6) 0.024 2.8 (1.1e6.8) 0.40 (0.1e3.5)
Nonusers 59 (28.5) 148 (71.5)
Drug use
Users 13 (50.0) 13 (50.0) 0.023 2.5 (1.1e5.8) 2.1 (0.3e14.8)
Nonusers 57 (28.2) 145 (71.8)
DM history
Diabetics 17 (47.2) 19 (52.8) 0.02 2.3 (1.1e4.9) 2.7 (1.02e6.99)
Nondiabetics 53 (27.6) 139 (72.4)
Patient category
Previously treated 69 (31.1) 153 (68.9) 0.79 2.3 (0.3e19.7) ND
New cases 1 (16.7) 5 (83.3)
Second-line drugsb
Yes 15 (57.7) 11 (42.3) 0.002 3.6 (1.6e8.4) 1.8 (0.7e4.8)
No 55 (27.2) 147 (72.8)
X-ray lesionsc
Moderate &extensive 51 (45.1) 62 (54.9) 0.000 4.3 (2.3e8.1) 5.9 (2.5e13.9)
Mild 18 (16.1) 94 (83.9)
Drug resistance
Four or more drugs 57 (31.7) 123 (68.3) 0.541 1.2 (0.6e2.5) ND
Less than four drugs 13 (27.1) 35 (72.9)
Drug regimens
Km, Ofx, Cs, Eto, PAS 61 (29.2) 148 (70.8) 1.0 1.4 (0.3e7.1) 0.6 (0.09e4.4)
Cm, Lfx, Cs, Eto, PAS,
Clr, Amx/Clv
7 (70.0) 3 (30.0) 0.07 8.2 (1.03e64.9) 0.7 (0.03e15.7)
Km, Ofx, Cs, Eto, PAS, Ed 2 (22.2) 7 (77.8)
Conversion time (mo)e
2 37 (24.8) 112 (75.2) 0.001 3.6 (1.2e10.8) 3.7 (1.2e11.7)
<2 4 (8.3) 44 (91.7)
History of TBf
5 y 11 (31.4) 24 (68.6) 0.961 1.02 (0.5e2.2) ND
<5 y 58 (31.0) 129 (69.0)
Bold indicates significant association at a p-value 0.05.
Amx/Clv Z amoxicillin/clavulanate; CI95 Z 95% confidence interval; Clr Z clarithromycin; Cm Z capreomycin; Cs Z cycloserine;
DM Z diabetes mellitus; E Z ethambutol; Eto Z ethionamide; Km Z kanamycin; Lfx Z levofloxacin; MDR-TB Z multidrug-resistant
tuberculosis; ND Z not included in the logistic model, insignificant by bivariate analysis; Ofx Z ofloxacin; OR Z odds ratio;
PAS Z p-aminosalicylic acid; TB Z tuberculosis.
a Using stepwise logistic regression, excluding extrapulmonary and not converted cases.
b History of previous use of any of the second-line drugs.
c Three cases were extrapulmonary TB.
d The reference group.
e Thirty-one cases were excluded: 28 not converted and three extrapulmonary.
f Six new cases were excluded.
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On the other hand, an increased risk of poor treatment
outcome of MDR-TB was documented among dia-
betics.5,28e30 In addition, diabetes may act as a potenti-
ating factor of the adverse effects of anti-TB drugs,especially those related to renal dysfunction and periph-
eral neuropathy.5 In light of the previous evidence,
detection of diabetes comorbidity is strongly required.
Active screening for diabetes among TB patients is sug-
gested as a more cost-effective measure than screening for
1002 M.A. Gadallah et al.TB among diabetics, especially in countries with a low TB
burden, where the yield of the screening for TB will be
low.31 In Egypt, as a low TB-burden country,3 screening for
diabetes among TB cases may be a plausible option, to be
incorporated within the TB control program.
Extension of lung tissue destruction was found to be an
independent predictor of the treatment outcome with a
sixfold increase in the risk of poor outcome with more
destruction. This finding was previously documented in
many studies in which the presence of cavity and extensive
disease was associated with a poor bacteriologic
response.19,30,32
Bacteriological improvement as well as the infectious
status of patients was determined by the sputum culture
conversion, and this factor was found to be a significant
predictor for treatment outcome. Earlier conversion in-
creases the likelihood of successful outcome, and it could
be used as an interim indicator of the outcome. Similar
results were observed in India and Latvia.13,33 The median
time to culture conversion in the current study was 60 days,
similar to that reported from Latvia (60 d) and Georgia
(68 d),33,34 but shorter than that from Armenia (3.7 mo).35
This relatively long conversion time among Armenians was
due to the presence of a high level of ofloxacin resis-
tance.35 Delayed culture conversion was previously found
to be associated with male sex, smoking, low body mass
index, resistance to second-line drugs, and extensive lung
affection with the presence of cavities.33e35 Patients with
such characteristics should be targeted with more aggres-
sive management, not only for the sake of a better prog-
nosis, but also to shorten the period of infectiousness.
In conclusion, about 69% treatment success was ach-
ieved with the first national treatment cohort of MDR-TB
cases. The high mortality rate highlighted the importance
of continuing the efforts for rapid diagnosis and treatment.
Predictors of unsuccessful outcome included moderate or
extensive lung affection, delay of sputum culture conver-
sion to 2 months or more, and a history of diabetes.Acknowledgments
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